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To the Editor,
Non-vitamin-K antagonist oral anticoagulants (NOACs), 
including dabigatran (a direct factor IIa [FIIa] inhibitor) 
increasingly replace the vitamin K antagonists (VKAs) for 
favorable risk–benefit profile [1] and lower risk of major 
bleeding [2] in atrial fibrillation. NOACs also significantly 
reduce the risk of recurrent venous thromboembolism 
(VTE), and compared with VKAs present lower risk of 
bleeding in this group [3]. The use of NOACs increases in 
VTE prevention, even though in the setting of surgical emer-
gency or life-theratening bleeding, the NOAC therapy may 
be dangerous [4].
In 2015, the FDA approved idarucizumab for dabigatran 
reversal in emergency situations [5]. Idarucizumab is a mon-
oclonal antibody fragment that binds dabigatran with high 
affinity, and presents good clinical outcomes [5, 6]. Cur-
rent European Heart Rhythm Association (EHRA) practi-
cal guidelines recommend idarucizumab for life-threatening 
bleeding, or prior to emergency surgery in dabigatran treated 
patients [7].
Clinical experience with idarucizumab in cardiac surgery 
is currently limited. In our institution, we managed several 
dabigatran-treated patients in emergency cardiosurgical set-
ting [8]. In previous cases, the clinical decision to adminis-
ter idarucizumab was made following emergency laboratory 
assessment of baseline dabigatran level (both individuals 
required an open-heart surgery for acute aortic syndrome) 
[8]. However, in specific clinical scenarios, monitoring of 
dabigatran level may be challenging and potentially impede 
the decision to use the expensive idarucizumab preparation 
based just on uncertain dabigatran intake history, and expos-
ing the patient to the risk of excessive (and potentially lethal) 
surgical bleeding, if dabigatran intake history is uncertain.
We report a case of a 63-years-old patient who received 
dabigatran for VTE and required emergency coronary artery 
bypass grafting (CABG) for an acute coronary syndrome 
(ACS) with coronary anatomy precluding percutaneous 
coronary intervention (PCI), in whom the preoperative dabi-
gatran level measurement was futile because of interferences 
with other thrombin inhibitors.
Case presentation
A 63-years-old male patient with a history of stable coro-
nary artery disease (CAD), previous myocardial infraction 
(MI), deep venous thrombosis, polycythemia vera and arte-
rial hypertension was admitted to our Institution (tertiary 
cardiac care center) for the surgical management of a new-
onset ACS in form of ST-segment elevation MI. He received 
dabigatran due to VTE (2 × 150 mg/day; last dose intake on 
the day of surgery) [3]. The patient was admitted to a local 
hospital due to severe chest pain. As soon as the ACS diag-
nosis was made, the coronary angiography was performed, 
showing a multi-vessel coronary disease with critical ste-
nosis (99%) of three arteries, and impending occlusion of 
the critically stenotic left main coronary artery (the right 
coronary artery was recessive). Because of the unfavorable 
anatomy, the patient was consulted online with the emer-
gency Heart Team, started on unfractionated heparin (UFH) 
in continuous infusion, and transferred to our department for 
emergency CABG.
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The surgical Team was called in, and dabigatran level, 
thrombin time, reptilase time, activated partial thrombo-
plastin time (APTT) and prothrombin time were measured 
on admission. His renal function was preserved (estimated 
glomerular filtration rate was 75 ml/min).
Dabigatran plasma concentration was determined on the 
BCS-XP automated analyzer (Siemens Healthcare Diagnos-
tics Products GmbH, Marburg, Germany), using the Hemo-
clot thrombin inhibitors (HTI) assay (Hyphen BioMed, 
Neuville-Sur-Oise, France). The assay based on modified 
diluted thrombin time was calibrated with the calibrators 
 (Biophen® Dabigatran Calibrator Low) containing differ-
ent concentrations of dabigatran (0, 56 and 108 ng/mL). A 
set of two levels control plasmas of dabigatran  (Biophen® 
Dabigatran Control Low) was used for the quality control of 
measurements. Reproducibility at dabigatran concentrations 
of 29 and 80 ng/mL were 12.7 (n = 10) and 8.7% (n = 10), 
respectively.
Unfortunately, the measurement of dabigatran plasma 
concentration was non-diagnostic because of the continuous 
UFH infusion. Nevertheless, the laboratory test was repeated 
five times in different time intervals. All laboratory results 
are present in Table 1. In spite of the inability to measure the 
dabigatran concentration, the patient received 5 g of intrave-
nous idarucizumab in two 50-ml bolus infusions (each con-
taining 2.5 g of idarucizumab, no more than 15 min apart, 
directly before the operation).
After idarucizumab administration, CABG in normo-
thermic cardiopulmonary bypass (CPB) followed. The 
saphenous vein grafts were placed to marginal and diagonal 
coronary arteries, and the left internal mammary artery was 
grafted to the left anterior descending coronary artery, fol-
lowing the standardized procedures. CPB time was 97 min, 
aortic cross clamp was 52 min, the overall procedural time 
was 140 min. Despite the scrupulous surgical hemostasis, 
the postoperative bleeding, according to the universal defini-
tion of perioperative bleeding in cardiac surgery, was severe 
[9]. The chest tube output was 840 ml after 24 h, and a total 
of two units of red blood cells, four units of platelets and 
eight units of fresh frozen plasma were administered in the 
first 24 h after the procedure.
During the postoperative course, the patient required 
antibiotics for postoperative pneumonia, diuretic treatment 
and intensive pulmonary rehabilitation. Antiplatelet regimen 
with aspirin (150 mg/day) was reinitiated on postoperative 
day 1. Dabigatran (2 × 150 mg) was restarted on postopera-
tive day 3. On postoperative day 10, the patient was dis-
charged to a local rehabilitation facility.
Discussion
In contrast to vitamin K antagonists, dabigatran is reported 
to have a shorter half-life and thus narrower therapeutic 
window. In patients with normal renal function, the resto-
ration of hemostasis is expected within 12–24 h after last 
dose intake [10]. Surgery or intervention should ideally be 
deferred, until 24 h after the last dose [10]. However, the 
real-life clinical practice shows that there are many situa-
tions, where reversal of dabigatran is required immediately. 
RE-VERSE AD trial demonstrated that idarucizumab is 
efficacious in dabigatran reversal [5]. Of note, in the RE-
VERSE AD trial, in each case dabigatran and idarucizumab 
plasma levels were measured to assess the dabigatran rever-
sal effect [5, 6].
The American Heart Association Scientific Statement 
from 2017 suggests for major bleeding in the event of dabi-
gatran intake in emergency cases: compression when pos-
sible, supportive measures, and upfront idarucizumab [11]. 
Following the RE-VERSE AD trial, also in real-life cases 
Table 1  Laboratory findings in patient with ACS and receiving dabigatran treatment with continuous heparin infusion
CPB Cardio-pulmonary bypass, ND not done, PT prothrombin time, RT reptilase time, APTT activated partial thromboplastin time, TT thrombin 
time
Measurement
I (17:30) II (18:20) III (21:40) IV (22:30) V (24:00)
Time period Baseline 50 min 4 h 10 min 5 h 00 min 6 h 30 min
Patient clinical status Admission to the 
hospital, continuous 
heparin infusion
Preoperative depart-
ment, continuous 
heparin infusion
Just before surgery, 
directly before idaru-
cizumab administra-
tion
Cardiac surgery- CPB, 
full dose heparin 
therapy
After CPB, heparin 
reversal using 
protamine
TT (s) [16.0–21.0] 81.3 > 150 25.2 > 150 25.5
RT (s) [16.0–22.0] 14.2 14 13.2 13 14.2
APTT (s) [25.9–36.6] 151.6 > 300 57.1 > 300 48.3
PT (s) [10.4–13.0] 15.3 > 170 14.4 > 170 17.6
DABIGATRAN level 
(ng/mL)
37 ND 33 ND 57
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dabigatran laboratory monitoring is performed before idaru-
cizumab administration [8, 12, 13].
However, in expert opinions, in life-threatening situa-
tions, when the last dose of dabigatran was intake < 12 h or 
there is uncertainty about the timing of last ingestion, it may 
be necessary to consider idarucizumab before the dabigatran 
level the results are known [12, 14]. Still, there are no spe-
cific recommendations for dabigatran level monitoring after 
idarucizumab administration.
Our patient, who was taking dabigatran for VTE prophy-
laxis, required a life-saving CABG, and in this specific clini-
cal scenario the continuous preoperative infusion of UFH 
was mandatory [15]. Both anticoagulants (dabigatran and 
heparin) inhibit the same level of coagulation cascade: dabi-
gatran is a direct thrombin inhibitor, while heparin inhibits 
thrombin indirectly [16]. Therefore, because dabigatran and 
heparin have similar effects on thrombin, the coagulation 
tests used were clinically not useful for decision making.
The HTI method is based on the measurement of the 
diluted tested plasma clotting time after addition of the 
constant amount of human thrombin. Prolonged clotting 
times are associated with higher dabigatran concentrations. 
However, the HTI assay does not contain any heparin inhibi-
tors, which is why heparin (or other thrombin inhibitors) 
present in the tested sample may interfere with the assay, 
and prolong the clotting time, producing falsely high plasma 
concentrations of dabigatran.
Normal reptilase time, and at the same time prolonged 
thrombin time, indicate that heparin is present in all tested 
samples. Thus, one might speculate that the dabigatran 
concentrations in samples I, III and V are falsely increased, 
however it is difficult to estimate how much. The thrombin 
time, prothrombin time and APTT measurement above the 
normal reference range in samples II and IV suggest that 
these samples contained heparin at very high concentrations. 
It was impossible to measure the concentration of dabigatran 
in these samples using the HTI.
Fast but reliable measurement of dabigatran concentra-
tions in patients concomitantly receiving heparin is a chal-
lenge. The gold standard in accurate dabigatran concentra-
tions measurement is liquid chromatography/tandem mass 
spectrometry (LC–MS/MS) [17], however, the availability of 
this method is limited, especially in the emergency setting. 
The HTI belongs to the group of commercially available 
“specific coagulation tests”, which is favorable to LC–MS/
MS in some aspects, though susceptible to interference by 
heparin [18].
The new commercially available test for dabigatran 
quantification irrespectively of heparin intake is the 
chromogenic  Innovance® DTI Assay (Siemens Health-
care Diagnostics Products GmbH, Marburg, Germany). 
According to the manufacturer, dabigatran measurement 
assays are not influenced by heparin concentrations of 8 
and 15 IU/mL, respectively. Another test based on diluted 
thrombin time Hemosil Direct Thrombin Inhibitor (Instru-
mentation Laboratory) is insensitive to UFH up to 2.2 IU/
mL. In any case, care must be taken during sampling, to 
avoid additional contamination of test tubes with heparin.
Our case showed, that there are emergency situations, 
where laboratory measurement of dabigatran level may not 
be clinically useful because of drugs interactions that mask 
the anticoagulant effect of dabigatran. In such cases, HTI 
assay may be unrevealing. In life-threatening situations, 
when urgent surgery/procedure cannot be delayed, and if 
the patient received dabigatran within < 12 h (or when the 
timing of last dose intake is uncertain), idarucizumab should 
be administered without dabigatran level monitoring.
There is also a question why we observed an exces-
sive postoperative bleeding despite idarucizumab admin-
istration. In previous cases the observed bleeding was 
moderate, however it might be speculated that the longer 
procedural time was a reason to transfuse the patient intra-
operatively, while in the current case, with shorter pro-
cedural time, the transfusions followed in the intensive 
care unit [5]. Furthermore, there is evidence that plasma 
dabigatran levels may increase by up to 96% of the base-
line value after successful initial neutralization by idaru-
cizumab due to redistribution, and another idarucizumab 
dose is required [12]. Because of nondiagnostic measure-
ment, we cannot exclude this phenomenon in our patient.
In conclusion, we report that dabigatran level monitor-
ing may not always be feasible in patients requiring idaruci-
zumab before an emergency cardiac surgery if UFH infusion 
is started. In our case, due to common affinity of dabigatran 
and heparin to thrombin, objective measurement of dabi-
gatran could not be performed with the available test. We 
conclude that in a patient with any suspicion of recent dabi-
gatran intake, in whom the drug level cannot be measured 
and the surgery deferred, idarucizumab should be adminis-
tered in any case. Heparin insensitive dabigatran measure-
ments should be preferred in cardiac surgery centers.
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